

## **Nevada Medicaid**

Submit fax request to: 855-455-3303

Please note: All information below is required to process this request.

## Zolgensma® Prior Authorization Request Form DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED.

Member Information (required)				Provider Information (required)				
Member Name:				Provider Name:				
Insurance ID#:				NPI#:		Specialty:		
Date of Birth:				Office Phone:				
Street Address:				Office Fax:				
City: State: Zip:				Office Street Address:				
Phone:				City:		State:	Zip:	
Medication Information (required)								
Medication Name:				Strength:		Dosage Form:		
☐ Check if requesting <b>brand</b>				Directions for Use:	L			
☐ Check if request is for <b>continuation of therapy</b>								
Clinical Information (required)								
Select the diagnosis below: (and attach supporting documentation to the PA request)								
☐ The recipient has a diagnosis of symptomatic Type I or Type II Spinal Muscular Atrophy (SMA) confirmed by a neurologist with expertise in the diagnosis of SMA								
☐ The recipient has a diagnosis of Spinal Muscular Atrophy (SMA) based on the results of SMA newborn screening with three copies or fewer of Survival Motor Neuron 2 (SMN2)								
□ Other diagnosis: ICD-10 Code(s):								
Clinical information: (attach any other information the physician feels is important to this review)								
Is the recipient 2 years of age or younger?								
Is the recipient dependent on invasive ventilation or tracheostomy or on non-invasive ventilation beyond use for naps and nighttime sleep?								
□ Yes □ No								
Does the recipient have homozygous gene deletion or mutation of the Survival Motor Neuron 1 (SMN1) gene (e.g., homozygous deletion of exon 7 at locus 5q13)?   Yes  No								
Does the recipient have compound heterozygous mutation of the SMN1 gene (e.g., deletion of SMN1, exon 7 [allele 1] and mutation of								
SMN1 [allele 2])? ☐ Yes ☐ No								
Will the recipient's medical records (e.g., chart notes, laboratory values) be submitted documenting that the recipient's anti-AAV9 antibody								
titers are less than or equal to 1:50? ☐ Yes ☐ No								
Will the recipient receive concomitant SMN modifying therapy (e.g., Spinraza®)? ☐ Yes ☐ No								
Is the medication prescribed by a neurologist with expertise in the diagnosis of SMA?   Yes  No								
Has the recipient ever received Zolgensma® treatment in their lifetime? ☐ Yes ☐ No								
	This request may be de							

This form may be used for non-urgent requests and faxed to 1-800-527-0531.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. If you are not the intended recipient, please notify the sender immediately.

FA-166 Page 1 of 1